Testosterone replacement drugs, a $1.6 billion market for Eli Lilly and Co. and others, boosted the odds of having a heart attack, stroke or dying by 29 percent in one of the first studies weighing the therapy's cardiovascular risks.
U.S. lawmakers, influenced by companies including Indianapolis-based Eli Lilly and Co., Cisco Systems Inc. and Qualcomm Inc., are considering the second set of patent-law changes in three years as the courts try to race ahead of Congress.
Eli Lilly and Co. has been counting on torrid growth in China to help offset losses from patent expirations in other markets, but now slower growth in the Chinese economy and bribery allegations against Lilly and two other drugmakers have hampered Lilly’s growth there.
The Indiana-based system that operates three hospitals in the Indianapolis area said it is trying to cut its expenses by as much as $500 million, or 20 percent.
A consortium of Indiana University, Purdue University and University of Notre Dame can operate for another five years with the grant funds.
The drugmaker has become too reliant on its remaining pipeline of drugs under development for growth as it deals with patent expirations to big sellers and drug-development setbacks, a Jefferies analyst wrote.
Indianapolis-based Novia CareClinics LLC was a pioneer in operating primary care clinics for employers. In 2012, Novia had 175 employees and more than $15 million in revenue.
More than 60 companies plan to participate in the three-day Indy Do Day volunteer marathon, which kicks off Thursday in conjunction with Eli Lilly and Co.’s Global Day of Service.
In a series of presentations, Lilly executives stretched themselves in four directions at once to convince investors and stock analysts that the company will bend but not break next year, and then snap back stronger than ever in 2015.
Psoriasis is linked to higher rates of heart disease and diabetes, and a third of patients also develop a form of arthritis. About 125 million people worldwide have the skin condition, including 7.5 million Americans.
Eli Lilly and Co. said Thursday that meeting its sale target will be a challenge. It plans to repurchase $5 billion in shares and introduce new diabetes drugs to help navigate through patent losses. Another immediate hurdle: Obamacare.
Indiana University Health now says it will cut more than 900 jobs in a reorganization. That's at least 100 more than announced nearly three weeks ago.
Eli Lilly said a potential breast cancer treatment missed its main goal in a late-stage study. However, the drugmaker will seek approval to use the treatment in stomach cancer patients after ramucirumab performed better in a separate study.
Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.
Part of the funding will go to an existing study of drugs from Eli Lilly and Co. and others to see whether they can ward off the disease in people who inherited genes that predestine them to get Alzheimer’s.
Major health insurers like WellPoint Inc. are in line for another year of growth, as the health care overhaul implements key elements in its push to cover millions of uninsured people.
The Indianapolis-based hospital system said Thursday it must make the cuts because fewer patients have been coming to hospitals and payment rates for its services have been declining.
With a half-dozen new products lined up for approval within two years, the fight to win the growing $22 billion U.S. diabetes market is expected to intensify.
Eli Lilly and Co. said it is investigating allegations its employees paid Chinese doctors at least $4.9 million in bribes and kickbacks to promote the sales of two diabetes drugs.
If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat.
